Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial

Community-acquired bacterial pneumonia (CABP) is a significant cause of morbidity and mortality worldwide. In the US, influenza and pneumonia are the eighth leading cause of death in people ≥65 years of age (Deaths, 2019). Approximately 1.3 million episodes of CABP occur in adults ≥65 years of age each year in the US (Yu et al., 2012). In the Etiology of Pneumonia in the Community (EPIC) study, approximately 4% of patients had the atypical pathogens M. pneumoniae, C. pneumoniae, an d L. pneumophila identified (Jain et al., 2015).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research